Hot Low Price Stocks To Watch For 2019

They say that big things come in small packages, and sometimes the same can be said about stock prices. There are plenty of stocks trading in the single digits, and while most of them — let’s face it — are there for a reason, risk-tolerant investors can sometimes find some real gems among low-priced equities. 

Sirius XM Holdings (NASDAQ:SIRI), Glu Mobile (NASDAQ:GLUU), Fitbit (NYSE:FIT), GoPro (NASDAQ:GPRO), Zynga (NASDAQ:ZNGA), Rite Aid (NYSE:RAD), and Groupon (NASDAQ:GRPN) are some of the big names with low prices that I’m watching these days. Let’s take a closer look at these seven stocks trading for $7 or less. 

Image source: Sirius XM Holdings.

1. Sirius XM Holdings — $6.94

Not every stock trading in the single digits is a loser. Sirius XM stock has been a nearly 140-bagger since bottoming out at a nickel in 2009. The satellite radio provider has been a beast over the years. The shares are trading higher for the 10th year in a row. 

Hot Low Price Stocks To Watch For 2019: Qiagen N.V.(QGEN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Barclays reiterated their buy rating on shares of Qiagen (NASDAQ:QGEN) in a research report report published on Thursday. Barclays currently has a $43.00 target price on the stock.

  • [By Brian Orelli]

    Qiagen (NYSE:QGEN), the molecular testing and lab supply company, started the year off with growth at the low end of its yearly guidance, although the first-quarter sales number was in line with where management expected to start the year.

  • [By Joseph Griffin]

    Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The company had revenue of $377.20 million during the quarter, compared to analysts’ expectations of $376.89 million. equities analysts forecast that Qiagen NV will post 1.34 EPS for the current fiscal year.

  • [By Ethan Ryder]

    These are some of the media headlines that may have effected Accern Sentiment’s scoring:

    Get Coty alerts:

    Accused Bigamist from San Angelo is On the Run Again (sanangelolive.com) Cosmetics Manufacturer Coty Takes Retail Space in Times Square (commercialobserver.com) Analyzing Colgate-Palmolive (CL) and Coty (COTY) (americanbankingnews.com) 3 Movers of Yesterday- Coty Inc. (NYSE:COTY), Alphabet Inc. (NASDAQ:GOOG), QIAGEN NV (NYSE:QGEN) (journalfinance.net) Trending Hot Stock’s Analysis – Coty Inc. (NYSE:COTY) (nasdaqjournal.com)

    A number of research firms recently commented on COTY. BMO Capital Markets raised their price objective on shares of Coty from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, February 9th. JPMorgan Chase raised their price objective on shares of Coty from $15.00 to $17.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Citigroup raised their price objective on shares of Coty from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Barclays set a $20.00 price objective on shares of Coty and gave the company a “hold” rating in a research note on Saturday, February 10th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Coty in a research note on Friday, February 9th. Five analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $19.71.

  • [By Joseph Griffin]

    Qiagen (NYSE: QGEN) is one of 91 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Qiagen to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.

Hot Low Price Stocks To Watch For 2019: Activision Blizzard, Inc(ATVI)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    Wall Street is a fan of gaming these days. Activision Blizzard (NASDAQ:ATVI), the video game industry’s leading publisher, has trounced the broader market by notching 21% growth so far in 2018 compared to a 3% gain for the S&P 500.

  • [By Motley Fool Staff]

    Activision Blizzard (NASDAQ:ATVI), Electronic Arts (NASDAQ:EA), and Take Two Interactive (NASDAQ:TTWO) have each launched professional esports leagues this year, while advertising and sponsorships are expected to make up three-quarters of the industry’s nearly $1 billion of revenue. And the recent announcement that Nielsen Holdings (NYSE:NLSN) will apply its TV rating expertise to Activision’s esport events could be the catalyst that unleashes a floodgate of media buying.

  • [By TD Ameritrade]

    These changes are also going to affect the Consumer Discretionary and Information Technology sectors. Here’s how some companies will shift around:

    Companies that are currently within the Media Industry part of the Consumer Discretionary sector will become a part of the Communications Services sector. For example, Walt Disney Co. (NYSE: DIS) and Comcast Corporation (NASDAQ: CMSCA) will join the new sector.
    Select companies that are currently in the Internet & Direct Marketing Retail sub-industry in the Consumer Discretionary sector will move to the new sector. Netflix, Inc. (NASDAQ: NFLX) and TripAdvisor Inc. (NASDAQ: TRIP) are two of them.
    Some companies that are currently in the Information Technology sector, such as Alphabet Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Facebook Inc. (NASDAQ: FB) and Activision Blizzard, Inc. (NASDAQ: ATVI), will be grouped in the Communications Services sector.

    In addition, the Internet & Direct Marketing Retail sub-industry in the Consumer Discretionary sector will now include all online marketplaces for consumer products and services, regardless of whether or not they actually hold inventory. Alibaba Group Holding Ltd. (NYSE: BABA), eBay Inc. (NYSE: EBAY), Mercado Libre Inc. (NASDAQ: MELI), among others, will now be a part of the Consumer Discretionary sector instead of the Information Technology sector, according to S&P Dow Jones Indices and MSCI.

  • [By Travis Hoium]

    This isn’t the end of Fortnite, and it’s still one of the most popular games in the world, but it may not be the threat competitors feared it could be. And with new games coming later this year, we could see powerhouses like Activision Blizzard (NASDAQ:ATVI), Electronic Arts (NASDAQ:EA), and Take-Two Interactive (NASDAQ:TTWO) take power back in the industry. 

  • [By Demitrios Kalogeropoulos]

    Shares of video game giant Activision Blizzard (NASDAQ:ATVI) outpaced the market last month, rising 15% compared to a 0.4% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.

Hot Low Price Stocks To Watch For 2019: REGENXBIO Inc.(RGNX)

Advisors’ Opinion:

  • [By Stephan Byrd]

    These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get REGENXBIO alerts:

    Quant Scorecard Under Review For REGENXBIO Inc. (NasdaqGS:RGNX) (derbynewsjournal.com) Regenxbio Inc (RGNX) AroonUp Technicals Showing Momentum Building (parkcitycaller.com) Showing Signs of Life? Stock Update on REGENXBIO Inc. (NASDAQ:RGNX) (parkcitycaller.com) Relative Strength Index (RSI 14) to Watch Mueller Water Products, Inc. (NYSE:MWA), REGENXBIO Inc. (NASDAQ … (stocksnewspoint.com) Are You Looking For Opportunity on Stock? REGENXBIO Inc. (RGNX) (nysestocks.review)

    A number of research firms have weighed in on RGNX. TheStreet upgraded REGENXBIO from a “d+” rating to a “c” rating in a research note on Friday, May 11th. ValuEngine upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. Raymond James set a $45.00 price objective on REGENXBIO and gave the company a “buy” rating in a research note on Tuesday, May 8th. Barclays reiterated an “overweight” rating and set a $48.00 price objective (up previously from $38.00) on shares of REGENXBIO in a research note on Wednesday, May 9th. Finally, BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $43.25.

  • [By Todd Campbell, Keith Speights, and Brian Feroldi]

    Biotechnology stocks can pop or drop because of clinical trial successes or failures, and that makes investing in biotech stocks riskier than investing in other industries. Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regenxbio (NASDAQ:RGNX), Regeneron Pharmaceuticals (NASDAQ:REGN), and AbbVie (NYSE:ABBV) worth considering. Read on to learn more about these companies and why some of our Motley Fools think they could be top stocks to add to portfolios this month.

  • [By Todd Campbell]

    Earlier this year, Novartis acquired AveXis for $8.7 billion to land AVXS-101, a potential one-and-done gene therapy for SMA. Using technology licensed from RegenXbio (NASDAQ: RGNX), one dose of AVXS-101 could restore SMN production by inserting a functioning copy of the missing or mutated SMN gene in motor neurons.

  • [By Joseph Griffin]

    Acceleron Pharma (NASDAQ: RGNX) and Regenxbio (NASDAQ:RGNX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

  • [By Keith Speights]

    Three gene therapy stocks have really stood out in the first half of the year. Sarepta Therapeutics (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), and Regnxbio (NASDAQ:RGNX) stocks have soared 120% or more since the beginning of 2018. Here’s what has made these the best gene therapy stocks of 2018 so far — and a look at whether or not they have even more room to run.

Hot Low Price Stocks To Watch For 2019: Medidata Solutions, Inc.(MDSO)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Low Price Stocks To Watch For 2019: Camden Property Trust(CPT)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Cryptaur (CURRENCY:CPT) traded 3.6% higher against the US dollar during the one day period ending at 8:00 AM E.T. on October 5th. One Cryptaur token can now be bought for about $0.0017 or 0.00000025 BTC on popular exchanges including HitBTC and LATOKEN. Cryptaur has a market capitalization of $11.97 million and approximately $36,809.00 worth of Cryptaur was traded on exchanges in the last day. Over the last week, Cryptaur has traded up 16.8% against the US dollar.

  • [By Ethan Ryder]

    Cryptaur (CURRENCY:CPT) traded 1.5% lower against the U.S. dollar during the 1-day period ending at 19:00 PM E.T. on September 22nd. Cryptaur has a total market capitalization of $10.45 million and $29,623.00 worth of Cryptaur was traded on exchanges in the last 24 hours. During the last seven days, Cryptaur has traded 7.5% higher against the U.S. dollar. One Cryptaur token can currently be bought for about $0.0014 or 0.00000022 BTC on exchanges including HitBTC and LATOKEN.

  • [By Shane Hupp]

    Barclays upgraded shares of Camden Property Trust (NYSE:CPT) from an equal weight rating to an overweight rating in a research report report published on Monday morning, Marketbeat reports. Barclays currently has $106.00 target price on the real estate investment trust’s stock, up from their previous target price of $87.00.

  • [By Motley Fool Transcribers]

    Camden Property Trust  (NYSE:CPT)Q4 2018 Earnings Conference CallFeb. 01, 2019, 11:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Camden Property Trust (NYSE:CPT) was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating in a report released on Thursday.

  • [By Ethan Ryder]

    Swiss National Bank reduced its position in Camden Property Trust (NYSE:CPT) by 5.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 451,000 shares of the real estate investment trust’s stock after selling 28,000 shares during the quarter. Swiss National Bank’s holdings in Camden Property Trust were worth $37,965,000 as of its most recent filing with the SEC.

Hot Low Price Stocks To Watch For 2019: Infinity Property and Casualty Corporation(IPCC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine lowered shares of Infinity Property and Casualty (NASDAQ:IPCC) from a strong-buy rating to a buy rating in a research report released on Saturday morning.

  • [By Shane Hupp]

    Berkshire Hathaway Inc. Class B (NYSE: BRK.B) and Infinity Property and Casualty (NASDAQ:IPCC) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

  • [By Stephan Byrd]

    Infinity Property and Casualty (NASDAQ:IPCC) and Hartford Financial Services Group (NYSE:HIG) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Leave a Reply

Your email address will not be published. Required fields are marked *